Skip to main content

Transplantation unit (Hematology)

There are two types of hematopoietic stem cell transplantation:

  • autotransplantation: autologous transplantation, using stem cells taken from the patient,
  • allotransplantation: allogenic transplantation,  using stem cells taken from a compatible brother or sister (known as a family or related transplant), or the stem cells of a voluntary and anonymous donor (an unrelated allogenic transplant). 

In practice, a transplant that follows a course of chemotherapy (the conditioning) takes place like a blood transfusion, the stem cells themselves lodging in the bone cavities where they multiply and ensure the restoral of the hematological and immune system. 

The first autologous transplantation of stem cells at the Jules Bordet Institute was carried out in 1981, followed by the first allogenic transplantation in 1984. 

Our programme was approved in 2009 by the Joint Accreditation Committee of the ISCT and EBMT or JACIE, recognising it as a centre of excellence for autologous and related and unrelated allogenic stem cell transplantations. 

The programme is growing, given the clear increase in transplant indications. We currently carry out about 35 autotransplants and 35 allotransplants a year. For the allotransplants we have a sterile unit with  6 laminar flow chambers.

Our programme is well supported by several specialists in medicine in addition to the hematologists specialising in transplantations, including infectiologists, intensivists and other specialists who possess the necessary skills to treat our patients. 

Also, in order to provide our patients with the most innovative treatment, the unit is engaged in clinical research
• Academic, in cooperation with the Belgian Hematological Society (BHS),  the EORTC, the LYSA, the IFM and the EBMT
• In cooperation with biotechnology firms for the handling of the graft in the framework of immunomodulation. 

Research projects


 

Project 1

A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with posttransplant cyclophosphamide in patients with a hematologic malignancy

Our team

Head of Department
- Prof Nathalie Meuleman -  Hematologist (Multiple Melomas and Plasmocytary Disorders: Autotransplants)

Head of Transplantation Unit
Prof Philippe Lewalle - Hematologist (Allotransplants)

Heads of the Clinics
- Prof Sebastian Wittnebel - Hematologist (Leukemias, Myelodysplasias and Allotransplants)

- Prof Marie Maerevoet -   Hematologist (Lymphomas and Lymphoproliferative Disorders: Autotransplant

Professor Emeritus
Prof Dominique Bron – Hematologist (Lymphomas and Chronic Lymphoid Leukemias)

Resident doctors 
Dr Chloé Spilleboudt (Allotransplants)
Dr Marie Vercruysen (Autotransplants)
Dr Adriano Salaroli (Allogreffe)

Qualitician
Aurélie Timmermans
Olivier Carabin

Head Nurse
Patrick Crombez

Transplant coordination and health education nurse
Jaivenois Marie France

Transplant coordinator
Sandra Michiels

19/02/2020

 Scientific publications

Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study.

Authors : Thibaud V, Denève L, Dubruille S, Kenis C, Delforge M, Cattenoz C, Somme D, Wildiers H, Pepersack T, Lamy T, Bron D
Year : 2021
Journal : J Geriatr Oncol

Immuno-comparative screening of adult-derived human liver stem/progenitor cells for immune-inflammatory-associated molecules.

Authors : Merimi M, Lagneaux L, Lombard CA, Agha DM, Bron D, Lewalle P, Meuleman N, Najimi M, Sokal EM, Najar M
Year : 2021
Journal : Inflamm Res

Biomarkers for Early Diagnosis of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients.

Authors : Debaugnies F, Mahadeb B, Nagant C, Meuleman N, De Bels D, Wolff F, Gottignies P, Salaroli A, Borde P, Voué M, Corazza F
Year : 2021
Journal : J Clin Immunol

New Anti-Leukemic Effect of Carvacrol and Thymol Combination through Synergistic Induction of Different Cell Death Pathways.

Authors : Bouhtit F, Najar M, Moussa Agha D, Melki R, Najimi M, Sadki K, Boukhatem N, Bron D, Meuleman N, Hamal A, Lagneaux L, Lewalle P, Merimi M
Year : 2021
Journal : Molecules
Volume : 26

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Authors : Shah J, Shacham S, Kauffman M, Daniele P, Tomaras D, Tremblay G, Casasnovas RO, Maerevoet M, Zijlstra J, Follows G, P Vermaat JS, Kalakonda N, Goy AH, Choquet S, Den Neste EV, Hill BT, Thieblemont C, Cavallo F, la Cruz F, Kuruvilla J, Hamad N, Bouabdallah R, Jäger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vasilakopoulos TP, Samal P, Nagy A, Ku M, Canales Albendea MÁ
Year : 2021
Journal : Future Oncol